Becker Capital Management Inc Amgen Inc Transaction History

Becker Capital Management Inc

$2.9 Billion
Q2 2024

A detailed history of Becker Capital Management Inc transactions in Amgen Inc stock. As of the latest transaction made, Becker Capital Management Inc holds 92,797 shares of AMGN stock, worth $29.3 Million. This represents 1.0% of its overall portfolio holdings.

Number of Shares

92,797

Previous 95,818 3.15%

Holding current value

$29.3 Million

Previous $27.2 Million 6.43%

% of portfolio

1.0%

Previous 0.94%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$262.75 - $319.31 $793,767 - $964,635	-3,021 Reduced 3.15%	92,797 $29 Million
Q1 2024 May 15, 2024	SELL	$268.87 - $324.56 $815,213 - $984,065	-3,032 Reduced 3.07%	95,818 $27.2 Million
Q4 2023 Feb 14, 2024	SELL	$255.7 - $288.46 $1.35 Million - $1.53 Million	-5,289 Reduced 5.08%	98,850 $28.5 Million
Q3 2023 Nov 14, 2023	SELL	$218.65 - $271.46 $486,277 - $603,727	-2,224 Reduced 2.09%	104,139 $28 Million
Q2 2023 Aug 11, 2023	SELL	$214.27 - $253.37 $1.47 Million - $1.74 Million	-6,862 Reduced 6.06%	106,363 $23.6 Million
Q1 2023 May 15, 2023	SELL	$225.79 - $275.2 $244,078 - $297,491	-1,081 Reduced 0.95%	113,225 $27.4 Million
Q4 2022 Feb 13, 2023	SELL	$229.03 - $291.01 $1.39 Million - $1.77 Million	-6,076 Reduced 5.05%	114,306 $30 Million
Q3 2022 Nov 14, 2022	BUY	$224.46 - $253.15 $457,225 - $515,666	2,037 Added 1.72%	120,382 $27.1 Million
Q2 2022 Aug 04, 2022	BUY	$230.71 - $256.74 $306,613 - $341,207	1,329 Added 1.14%	118,345 $28.8 Million
Q1 2022 May 12, 2022	BUY	$219.27 - $242.57 $761,086 - $841,960	3,471 Added 3.06%	117,016 $28.3 Million
Q4 2021 Feb 08, 2022	SELL	$198.88 - $227.6 $309,855 - $354,600	-1,558 Reduced 1.35%	113,545 $25.5 Million
Q3 2021 Oct 14, 2021	BUY	$212.27 - $248.7 $838,891 - $982,862	3,952 Added 3.56%	115,103 $24.5 Million
Q2 2021 Aug 12, 2021	BUY	$233.58 - $259.14 $645,147 - $715,744	2,762 Added 2.55%	111,151 $27.1 Million
Q1 2021 May 13, 2021	BUY	$221.91 - $258.6 $509,727 - $594,004	2,297 Added 2.17%	108,389 $27 Million
Q4 2020 Feb 10, 2021	BUY	$216.38 - $257.67 $104,078 - $123,939	481 Added 0.46%	106,092 $24.4 Million
Q3 2020 Nov 09, 2020	BUY	$234.65 - $260.95 $82,596 - $91,854	352 Added 0.33%	105,611 $26.8 Million
Q2 2020 Aug 11, 2020	SELL	$197.81 - $242.74 $87,234 - $107,048	-441 Reduced 0.42%	105,259 $24.8 Million
Q1 2020 May 07, 2020	BUY	$182.24 - $241.7 $1.03 Million - $1.36 Million	5,645 Added 5.64%	105,700 $21.4 Million
Q4 2019 Feb 11, 2020	SELL	$189.21 - $243.2 $251,460 - $323,212	-1,329 Reduced 1.31%	100,055 $24.1 Million
Q3 2019 Nov 14, 2019	SELL	$174.11 - $208.62 $507,878 - $608,544	-2,917 Reduced 2.8%	101,384 $19.6 Million
Q2 2019 Aug 08, 2019	SELL	$166.7 - $195.41 $2,167 - $2,540	-13 Reduced 0.01%	104,301 $19.2 Million
Q1 2019 May 08, 2019	SELL	$180.87 - $203.88 $387,604 - $436,914	-2,143 Reduced 2.01%	104,314 $19.8 Million
Q4 2018 Feb 04, 2019	SELL	$178.4 - $208.25 $781,927 - $912,759	-4,383 Reduced 3.95%	106,457 $20.7 Million
Q3 2018 Nov 05, 2018	SELL	$185.29 - $208.89 $199,001 - $224,347	-1,074 Reduced 0.96%	110,840 $23 Million
Q2 2018 Aug 03, 2018	SELL	$166.05 - $186.51 $1.01 Million - $1.13 Million	-6,057 Reduced 5.13%	111,914 $20.7 Million
Q1 2018 May 07, 2018	BUY	$169.43 - $198.0 $5,252 - $6,138	31 Added 0.03%	117,971 $20.1 Million
Q4 2017 Feb 13, 2018	SELL	$168.79 - $188.59 $475,987 - $531,823	-2,820 Reduced 2.34%	117,940 $20.5 Million
Q3 2017 Nov 02, 2017	SELL	$167.29 - $191.0 $329,226 - $375,888	-1,968 Reduced 1.6%	120,760 $22.5 Million
Q2 2017 Aug 11, 2017	BUY	N/A	122,728	122,728 $21.1 Million

Others Institutions Holding AMGN

# of Institutions

3,073

Shares Held

417M

Call Options Held

7.19M

Put Options Held

6.28M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $169B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Becker Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Becker Capital Management Inc with notifications on news.

Account

Becker Capital Management Inc Amgen Inc Transaction History